COX-2 inhibitors.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Author(s): Hawkey, C.J.
  • Source:
    Lancet. 1/23/1999, Vol. 353 Issue 9149, p307-314. 8p. 1 Color Photograph, 4 Diagrams, 5 Charts, 2 Graphs.
  • Additional Information
    • Subject Terms:
      ASPIRIN; ANALGESICS; PROSTAGLANDIN synthesis; CYCLOOXYGENASES; DRUG development; CHEMICAL inhibitors; PHYSIOLOGY; DRUG side effects
    • Abstract:
      In the past 100 years aspirin has demonstrated its value as an analgesic, anti-inflammatory, and antithrombotic agent. However, by 1938, it was clear that aspirin was gastrotoxic. Non-steroidal anti-inflammatory drugs (NSAIDs), developed since the 1960s, failed to achieve the goal of "a safer aspirin". The demonstration that inhibition of prostaglandin synthesis via a cyclo-oxygenase (COX) enzyme was central to both the therapeutic and toxic effects of aspirin and non-aspirin NSAIDs appeared to establish the principle of no gain without pain. This link may have been broken by drugs that selectively inhibit the inducible COX-2 enzyme. The COX enzyme is now a target of drug interventions against the inflammatory process. Might the "safe aspirin" be here at last? [ABSTRACT FROM AUTHOR]
    • Abstract:
      Copyright of Lancet is the property of Lancet and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)